| Ytd | -44.40% | |
| 1y | -77.53% |
| Open | 1.30 | Prev Close | 1.34 | Low | 1.27 | High | 1.33 | Mkt Cap | 6.39M |
| Vol | 61.66K | Avg Vol | 742.79K | EPS | -4.06 | P/E | N/A | Forward P/E | -0.32 |
| Beta | 0.79 | Short Ratio | 0.52 | Inst. Own | 0.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 1.31 | 200-d Avg | 1.63 | 1yr Est | 6.00 |
DRMA News
- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskinc
- Preorders can be made by visiting www.tomeskincare.com - - Dermata is ready to begin shipping orde
$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds up
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's
Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p
Dermata Therapeutics shares jumped 28.73% pre-market after reporting second-quarter results and prep
CRWV shares rose in pre-market trading after reporting better-than-expected Q2 results. BAOS, BOXL,
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday'
- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, e
- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch,
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the ana
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - D
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery Sy
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the ana
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skinca
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Fr
Dermata Therapeutics shares are trading higher Friday after the USPTO issued a notice of allowance f
Planet Labs (PL) stock rose in pre-market trading after better-than-expected Q4 sales and strong FY2
UPDATE: Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIO
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEG
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) is expected to issue its results before the ma
-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2
The Company's innovative acne kit represents a new approach to acne treatment by targeting the u
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combin
U.S. stock futures swung between gains and losses on Tuesday after Monday's declines. Futures of maj
U.S. stock futures swung between gains and losses on Tuesday after Monday’s declines. Futures of maj
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds up
Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C w